Literature DB >> 27175242

Chronic lymphocytic leukemia: treatment of relapse.

M Montillo1.   

Abstract

Despite significant advances in the frontline treatment of chronic lymphocytic leukemia (CLL), patients eventually experience disease progression. Treatment selection of relapsed disease depends upon a variety of factors, including patient age, performance status, duration of response to initial therapy, type of prior therapy, disease-related manifestations and genetic abnormalities within the CLL cells. This presentation offers synthetic overview of the options in this field.

Entities:  

Keywords:  allogeneic transplant; chemoimmunotherapy; chronic lymphocytic leukemia; monoclonal antibodies; relapse; resistance to purine analogs

Year:  2012        PMID： 27175242      PMCID： PMC4851199          DOI： 10.1038/leusup.2012.18

Source DB:  PubMed          Journal:  Leuk Suppl        ISSN： 2044-5210


  9 in total

Review 1.  State-of-the-art treatment of chronic lymphocytic leukemia.

Authors:  Michael Hallek
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2009

2.  National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.

Authors:  B D Cheson; J M Bennett; M Grever; N Kay; M J Keating; S O'Brien; K R Rai
Journal:  Blood       Date:  1996-06-15       Impact factor: 22.113

3.  p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias.

Authors:  H Döhner; K Fischer; M Bentz; K Hansen; A Benner; G Cabot; D Diehl; R Schlenk; J Coy; S Stilgenbauer
Journal:  Blood       Date:  1995-03-15       Impact factor: 22.113

4.  Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.

Authors:  K R Rai; B L Peterson; F R Appelbaum; J Kolitz; L Elias; L Shepherd; J Hines; G A Threatte; R A Larson; B D Cheson; C A Schiffer
Journal:  N Engl J Med       Date:  2000-12-14       Impact factor: 91.245

5.  Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.

Authors:  R N Damle; T Wasil; F Fais; F Ghiotto; A Valetto; S L Allen; A Buchbinder; D Budman; K Dittmar; J Kolitz; S M Lichtman; P Schulman; V P Vinciguerra; K R Rai; M Ferrarini; N Chiorazzi
Journal:  Blood       Date:  1999-09-15       Impact factor: 22.113

6.  Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.

Authors:  T J Hamblin; Z Davis; A Gardiner; D G Oscier; F K Stevenson
Journal:  Blood       Date:  1999-09-15       Impact factor: 22.113

7.  ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile.

Authors:  Adrian Wiestner; Andreas Rosenwald; Todd S Barry; George Wright; R Eric Davis; Sarah E Henrickson; Hong Zhao; Rachel E Ibbotson; Jenny A Orchard; Zadie Davis; Maryalice Stetler-Stevenson; Mark Raffeld; Diane C Arthur; Gerald E Marti; Wyndham H Wilson; Terry J Hamblin; David G Oscier; Louis M Staudt
Journal:  Blood       Date:  2003-02-20       Impact factor: 22.113

Review 8.  Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia.

Authors:  A Osterborg; R Foà; R F Bezares; C Dearden; M J S Dyer; C Geisler; T S Lin; M Montillo; M H J van Oers; C-M Wendtner; K R Rai
Journal:  Leukemia       Date:  2009-07-23       Impact factor: 11.528

9.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.

Authors:  Michael Hallek; Bruce D Cheson; Daniel Catovsky; Federico Caligaris-Cappio; Guillaume Dighiero; Hartmut Döhner; Peter Hillmen; Michael J Keating; Emili Montserrat; Kanti R Rai; Thomas J Kipps
Journal:  Blood       Date:  2008-01-23       Impact factor: 22.113
  9 in total
  1 in total

1.  Derivatisation of parthenolide to address chemoresistant chronic lymphocytic leukaemia.

Authors:  Xingjian Li; Daniel T Payne; Badarinath Ampolu; Nicholas Bland; Jane T Brown; Mark J Dutton; Catherine A Fitton; Abigail Gulliver; Lee Hale; Daniel Hamza; Geraint Jones; Rebecca Lane; Andrew G Leach; Louise Male; Elena G Merisor; Michael J Morton; Alex S Quy; Ruth Roberts; Rosanna Scarll; Timothy Schulz-Utermoehl; Tatjana Stankovic; Brett Stevenson; John S Fossey; Angelo Agathanggelou
Journal:  Medchemcomm       Date:  2019-08-01       Impact factor: 3.597
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.